Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana R. Halle(Vanderbilt University), Veronica Rotemberg(Memorial Sloan Kettering Cancer Center), Florentia Dimitriou(University Hospital of Zurich), Ryan J. Sullivan(Dana-Farber Cancer Institute), Anna K. Dewan(Vanderbilt University Medical Center), Nicholas R. Kurtansky(Memorial Sloan Kettering Cancer Center), Alexander M. Menzies(The University of Sydney), Douglas B. Johnson(Vanderbilt University), Sunandana Chandra(Northwestern University), T. Otto(Rutgers, The State University of New Jersey), Rebecca Irlmeier(Vanderbilt University Medical Center), Jessica C. Hassel(National Center for Tumor Diseases), Georgina V. Long(Westmead Hospital), Allison Betof Warner(Memorial Sloan Kettering Cancer Center), Farzana Y. Zaman(The Alfred Hospital), Jeffrey A. Sosman(Palmetto Hematology Oncology), Matteo S. Carlino(The University of Sydney), Meghan J. Mooradian(Massachusetts General Hospital), Prachi Bhave(Peter MacCallum Cancer Centre), Andrew Haydon(The Alfred Hospital), Fei Ye(UPMC Hillman Cancer Center), Jacob Choi(University of Illinois Chicago), Paras Mehta(Memorial Sloan Kettering Cancer Center), Steven T. Chen(Massachusetts General Hospital), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center)
Cited by 64
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k